Altynai Satylganova Selected Research

cagrilintide

12/2021	Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
1/2021	Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Altynai Satylganova Research Topics

Disease

4	Weight Loss (Weight Reduction) 12/2021 - 01/2020
3	Obesity 12/2021 - 01/2020
2	Overweight 12/2021 - 01/2020
1	Nausea 12/2021
1	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 01/2021
1	Type 2 Diabetes Mellitus (MODY) 01/2020
1	Weight Gain 01/2020

Drug/Important Bio-Agent (IBA)

3	Liraglutide FDA Link 12/2021 - 01/2020
2	cagrilintideIBA 12/2021 - 01/2021
1	GoldIBA 01/2021
1	Pharmaceutical PreparationsIBA 01/2021
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2020
1	Insulin (Novolin)FDA Link 01/2020

Therapy/Procedure

1	Drug Therapy (Chemotherapy) 01/2021
1	Glycemic Control 01/2020